Biomarkers by Oxford Global will explore the essential criteria for validating clinical biomarkers, shedding light on the steps and challenges involved.

Here, we speak to Matthias von Herrath about Biomarkers US 2023 and some current trends in the industry concerning research and technological development.

Here, we speak to UT Southwestern’s Shuang Liang about monitoring TREM2 as a non-invasive diagnostic biomarker for NASH.

A recent FNIH study demonstrates the effectiveness of non-invasive blood tests in diagnosing non-alcoholic steatohepatitis (NASH), potentially reducing the need for invasive liver biopsies and improving NASH diagnosis.

N-of-1 trials employ individualised treatments through double-blinded, randomised sequences to determine optimal approaches and enhance patient-doctor collaboration.

While biomarkers are integral to the identification and validation of disease treatment methods, there is a disconnect between existing validation approaches and their applications in commercialisation.

While the complexities associated with identifying tumour state and coordinating an effective immunotherapeutic response are many, pioneering healthcare providers are rising to the challenge.

Biomarkers in psychiatry may have the potential to overcome the challenges associated with complications such as depression, bipolar disorder, and generalised anxiety.

ICIs – immune checkpoint inhibitors – have changed the landscape of therapeutic treatment for cancer and improved survival rates for patients with advanced malignancies. However, the wide variability in clinical response is a significant limitation to treatment.

An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.

Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company's ultrasensitive biomarker assay technology.

We explore some of the different applications of AI in biomarkers for cancer analysis, including in urology and the characterisation of prostate cancer.